雷珠单抗与阿柏西普在治疗-延长方案中对新生血管性AMD最佳矫正视力的影响:一项随机临床试验
RIVAL试验在澳大利亚24个中心纳入281只未经治疗的活动性新生血管性AMD眼,随机接受0.5mg雷珠单抗或2.0mg阿柏西普,采用相同治疗-延长方案。
要点
- 12个月BCVA平均变化雷珠单抗7.2个字母,阿柏西普4.9个字母,差异未达统计学显著。
- 两组12个月内平均注射次数均为9.7次,率比1.00,无显著差异。
- 采用相同治疗-延长方案时,两药在1年内平均视力增益和注射负荷相当。
核心结论
- 在治疗-延长方案下,雷珠单抗与阿柏西普治疗新生血管性AMD在1年内平均视力增益和注射次数方面均无优势。
研究设计与样本
- RIVAL试验为随机临床试验,在澳大利亚24个中心纳入281只未经治疗的活动性新生血管性AMD眼,随机1:1接受0.5mg雷珠单抗或2.0mg阿柏西普,先3次每月注射后进入治疗-延长阶段,第12个月进行预设中期分析。
关键数值与推荐
- 纳入标准为继发于新生血管性AMD的活动性脉络膜新生血管且视力字母评分≥23。
- 主要结局指标为基线至12个月BCVA平均变化和注射次数。
临床怎么用
- 对于新生血管性AMD采用治疗-延长方案时,雷珠单抗与阿柏西普在1年内平均视力增益和注射负荷相似,选择可基于其他因素。
局限性
- 本文为预设12个月中期分析,随访至2年可能有助于识别两药优劣。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: To our knowledge, this is the first randomized clinical trial to compare visual outcomes and injection loads between ranibizumab and aflibercept using an identical treat-and-extend (TE) regimen for neovascular age-related macular degeneration (nAMD). OBJECTIVE: To report the results of the preplanned 12-month interim analysis of 2 predefined secondary efficacy end points of a randomized clinical trial. DESIGN, SETTING, AND PARTICIPANTS: The Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients (RIVAL) trial was conducted in 24 sites in Australia and included 281 treatment-naive eyes from 281 participants with active choroidal neovascularization secondary to nAMD and a visual acuity letter score of 23 or greater who were recruited between April 11, 2014, and October 31, 2015. A preplanned interim analysis was performed at month 12. Best-corrected visual acuity (BCVA) assessors and the central reading center, which determined treatment intervals, were masked to treatment assignments. INTERVENTIONS: Participants were randomized (1:1) to receive intravitreal injections of 0.5 mg of ranibizumab or 2.0 mg of aflibercept. After receiving 3 initial monthly injections, participants entered the TE phase. MAIN OUTCOMES AND MEASURES: Mean change in BCVA and the number of injections from baseline to month 12. RESULTS: Of 281 participants, 148 (52.7%) were women and the mean (SD) age was 77.7 (8.1) years. The baseline mean BCVA letter score (approximate Snellen equivalent) was 65.3 (20/50) in the ranibizumab arm and 65.1 (20/50) in the aflibercept arm. One hundred twenty-seven ranibizumab participants (90.1%) and 121 aflibercept participants (88.3%) completed month 12 with a mean (SD [Snellen equivalent]) BCVA letter score of 72.9 (15.5 [20/32]) and 70.5 (14.6 [20/40]), respectively. The mean change in BCVA letter scores from baseline to month 12 was 7.2 (95% CI, 5.5-8.9) for ranibizumab and 4.9 (95% CI, 3.1-6.6) for aflibercept (letter score difference, 2.3; 95% CI, -0.1 to 4.7; P = .06). The mean number of injections from baseline to month 12 was 9.7 in both the ranibizumab (SD, 2.8) and aflibercept (SD, 2.6) arms with a rate ratio of 1.00 (95% CI, 1.0-1.1; P = .86). CONCLUSIONS AND RELEVANCE: Our findings suggest that neither aflibercept nor ranibizumab for nAMD are superior to the other regarding the average visual acuity gains and number of injections during 1 year in a TE regimen. Further follow-up to 2 years may determine if advantages of one over the other can be identified. TRIAL REGISTRATION: Clinicaltrials.Gov identifier: NCT02130024.
引用
- Gillies MC, Hunyor AP, Arnold JJ, et al. Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. 2019. PMID: 30676617. doi:10.1001/jamaophthalmol.2018.6776
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。